Open AccessThrombotic Thrombocytopenic Purpura Associated With Ticlopidine in the Setting of Coronary Artery Stents and Stroke Prevention
Author(s) -
Charles L. Bennett,
Charles J. Davidson,
Dennis W. Raisch,
Peter D. Weinberg,
R. H. Bennett,
Marc D. Feldman
Publication year - 1999
Publication title -
archives of internal medicine
Language(s) - English
Resource type - Journals
eISSN - 1538-3679
pISSN - 0003-9926
DOI - 10.1001/archinte.159.21.2524
Subject(s) - ticlopidine , medicine , thrombotic thrombocytopenic purpura , stroke (engine) , antiplatelet drug , adverse effect , coronary artery disease , postmarketing surveillance , stent , surgery , clopidogrel , pediatrics , myocardial infarction , platelet , engineering , mechanical engineering
One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement. Recently, Hoffman-LaRoche Pharmaceuticals, following reports of 20 deaths from ticlopidine-associated TTP, updated the information about the hematologic adverse effects of the drug.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom